More on MRK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $120.76 |
|
|||
| Open | $121.50 | ||||
| 52 Wk High | $65.46 | ||||
| 52 Wk Low | $47.97 | ||||
| Day High | $121.90 | ||||
| Day Low | $118.83 | ||||
| P/E | 80.99 | ||||
| EPS | $1.47 | ||||
| Volume | 10,927,028 | ||||
- FDA approves Merck's KEYTRUDA and WELIREG combination for kidney cancer
- FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Ce
- Merck Animal Health to acquire poultry technology firm TARGAN
- Merck Animal Health to Acquire TARGAN
- Gilead and Merck announce successful HIV treatment trial results
- Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
- Merck and Gilead discontinue lung cancer drug combination trial
- Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
- MilliporeSigma Appoints New Heads of Discovery Solutions and Strategy & Business Development
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
Entities mentioned with MRK
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
